Skip to main content
. 2018 Oct 20;141(11):3144–3159. doi: 10.1093/brain/awy253

Figure 1.

Figure 1

Patient's LGI1 IgG blocks the binding of soluble LGI1 to ADAM23 and ADAM22. (A) Top: Coomassie staining of proteins contained in the medium of HEK293 LGI1-expressing cells (lanes 2 and 3) and HEK293 cells not expressing LGI1 (lanes 4 and 5) (total protein load in lanes 2 and 4, 25 μg; and in lanes 3 and 5, 12.5 μg). Bottom: Immunoblot of protein preparations shown in the upper Coomassie panel using a polyclonal LGI1 antibody; note that LGI1 is only present in the medium derived from HEK LGI1-expressing cells. (B) HEK293 cells expressing ADAM23 or ADAM22 (in magenta) bind soluble LGI1 (in green) present in the medium of HEK293 cells expressing LGI1 (B, top row) but not present in control medium (B, second row). When the medium with soluble LGI1 is preincubated with a representative patient's LGI1 IgG the binding of LGI1 to ADAM23 or ADAM22 is abrogated (B, third row); in contrast, no blocking of the binding is observed when the medium is preincubated with control IgG (B, fourth row). Scale bar = 20 μm.